3.20
+0.0433(+1.37%)
Currency In USD
| Previous Close | 3.16 |
| Open | 3.09 |
| Day High | 3.3 |
| Day Low | 3.09 |
| 52-Week High | 6.9 |
| 52-Week Low | 1.69 |
| Volume | 29,192 |
| Average Volume | 155,612 |
| Market Cap | 8.27M |
| PE | -1.02 |
| EPS | -3.13 |
| Moving Average 50 Days | 2.8 |
| Moving Average 200 Days | 2.78 |
| Change | 0.04 |
If you invested $1000 in Creative Medical Technology Holdings, Inc. (CELZ) since IPO date, it would be worth $0.39 as of August 22, 2025 at a share price of $3.203. Whereas If you bought $1000 worth of Creative Medical Technology Holdings, Inc. (CELZ) shares 5 years ago, it would be worth $188.43 as of August 22, 2025 at a share price of $3.203.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain
GlobeNewswire Inc.
Aug 13, 2025 1:01 PM GMT
PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administ
Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells
GlobeNewswire Inc.
Jul 17, 2025 1:15 PM GMT
PHOENIX, July 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has re
Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling
GlobeNewswire Inc.
Jul 11, 2025 12:01 PM GMT
PHOENIX, July 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has re